Prothrombin complex concentrates market

Prothrombin Complex Concentrates Market, by Type (3-FactorPCC and 4-Factor PCC), by Application (Acquired Coagulation Factor Deficiency, Congenital Coagulation Factor Deficiency, and Others), by End User (Hospital, Ambulatory Surgical Centres and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Request Free Sample

Sep 2021
CMI4647
149 Pages
Excel & Pdf
Pharmaceutical

Summary

Prothrombin complex concentrate is manufactured through a process of ion-exchange chromatography from the cryoprecipitate supernatant of large plasma pools after the removal of factor XI and antithrombin. These concentrates are used to treat and prevent bleeding in the case of hemophilia B if a pure factor IX is not present.

An emerging factor driving the prothrombin complex concentrate market growth is rising prevalence of hemophilia B

For instance, according to the Centers for Disease Control and Prevention (CDC) report, Hemophilia A occurs in 1 out of 5,000 live male births. It is around four times more common than Hemophilia B. Few effective treatments available for hemophilia require lifetime infusion of expensive drugs manufactured through recombinant biotechnology or from human plasma.

The global prothrombin complex concentrates market is estimated to be valued at US$ 771.2 million in 2021 and is expected to exhibit a CAGR of 10.2% over the forecast period (2021-2028).

Figure 1. Global Prothrombin Complex Concentrates Market Share (%) in Terms of Value, By Region, 2021

Increasing approval of product by regulatory bodies is expected to increase the growth of the global prothrombin complex concentrates market over the forecast period.

For instance, in 2013, CSL Behring has received the U.S. Food and Drug Administration (FDA) approval for Kcentra (Prothrombin Complex Concentrate) for the indication of urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients needing an urgent surgery or other invasive procedure.

Prothrombin Complex Concentrates Market Report Coverage

Report Coverage	Details
Base Year:	2020	Market Size in 2021:	US$ 771.2 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2021 to 2028
Forecast Period 2021 to 2028 CAGR:	10.2%	2028 Value Projection:	US$ 1,522.3 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Type: 3-Factor PCC, 4-Factor PCC By Application: Acquired Coagulation Factor Deficiency, Congenital Coagulation Factor Deficiency, Others By End User: Hospital, Ambulatory Surgical Centres, Others
Companies covered:	Octapharma AG, Nihon Pharmaceutical Co. Ltd., Grifols S.A., CSL Behring GmbH, Kedrion Biopharma Inc., Shire Plc, China Biologic Products Holdings, Inc., and Sanquin
Growth Drivers:	Increasing approval of product by regulatory bodies Increasing prevalence of hemophilia B
Restraints & Challenges:	Thrombotic complication related to PCC

Figure 2. Global Prothrombin Complex Concentrates Market Share (%), by Type, 2021

Global Prothrombin Complex Concentrates Market Restraint

The major factors that hinder the growth of the prothrombin complex concentrates market include thrombotic complication resulting from the use of prothrombin complex concentrates such as venous thromboembolism, micro vascular thrombosis, and myocardial infraction.

Key Players

Major players operating in the global prothrombin complex concentrates market include Octapharma AG, Nihon Pharmaceutical Co. Ltd., Grifols S.A., CSL Behring GmbH, Kedrion Biopharma Inc., Shire Plc, China Biologic Products Holdings, Inc., and Sanquin

Table of Content

*Browse 35 market data tables and 30 figures on "Prothrombin Complex Concentrates Market” - Global forecast to 2028

N/A

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the market during the forecast period (2021-2028)?

The global prothrombin complex concentrates market size is estimated to be valued at US$ 771.2 million in 2021 and is expected to exhibit a CAGR of 10.2% between 2021 and 2028.

What are the major factors driving the market growth?

Increasing approval of products and increasing prevalence of hemophilia B are expected to drive the market growth over the forecast period.

Which region holds the largest market share in the market?

North America holds the largest market share in the market.

What are the key factors hampering the growth of the market?

Major factor hampering the growth of the market includes the thrombotic complication related to PCC .

Which are the major players operating in the market?

Major players operating in the market include Octapharma AG, Nihon Pharmaceutical Co. Ltd., Grifols S.A., CSL Behring GmbH, Kedrion Biopharma Inc., Shire Plc, China Biologic Products Holdings, Inc. and Sanquin